These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2645874)

  • 41. [Comparative effectiveness of chrysanol and auranofin in rheumatoid arthritis].
    Atakhodzhaeva ZA; Sigidin IaA
    Ter Arkh; 1987; 59(12):30-3. PubMed ID: 3328906
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial.
    Giannini EH; Barron KS; Spencer CH; Person DA; Baum J; Bernstein BH; Kredich DW; Jacobs JC; Zemel LS; Gibbas D
    J Rheumatol; 1991 Aug; 18(8):1240-2. PubMed ID: 1941832
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A multi-center double blind prospective study of ridaura in the treatment of rheumatoid arthritis].
    Zhang NZ
    Zhonghua Nei Ke Za Zhi; 1992 Jul; 31(7):394-7, 443. PubMed ID: 1298591
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Psoriatic arthritis treated with oral zinc sulphate.
    Clemmensen OJ; Siggaard-Andersen J; Worm AM; Stahl D; Frost F; Bloch I
    Br J Dermatol; 1980 Oct; 103(4):411-5. PubMed ID: 7002197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Auranofin in the treatment of rheumatoid arthritis: a multicenter double-blind prospective clinical trial].
    Yang JL
    Zhonghua Nei Ke Za Zhi; 1993 Jul; 32(7):486-8. PubMed ID: 8275829
    [No Abstract]   [Full Text] [Related]  

  • 46. The efficacy and safety of auranofin compared to placebo in rheumatoid arthritis.
    Katz WA; Alexander S; Bland JH; Blechman W; Bluhm GB; Bonebrake RA; Falbo A; Greenwald RA; Hartman S; Hobbs T; Indenbaum S; Lergier JE; Lanier BG; Lightfoot RW; Phelps P; Sheon RP; Torretti D; Wenger ME; Wilske K
    J Rheumatol Suppl; 1982; 8():173-8. PubMed ID: 6813481
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Multicenter double-blind comparison of auranofin and Tauredon].
    Kaik B; Bröll H
    Wien Klin Wochenschr Suppl; 1984; 156():33-40. PubMed ID: 6442055
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Psoriatic arthritis. Long term treatment with auranofin.
    Tumiati B; Baricchi R; Bellelli A
    Clin Rheumatol; 1986 Jan; 5(1):124-5. PubMed ID: 3082571
    [No Abstract]   [Full Text] [Related]  

  • 50. A comparison of health-related quality-of-life measures for rheumatoid arthritis research. The Auranofin Cooperating Group.
    Bombardier C; Raboud J
    Control Clin Trials; 1991 Aug; 12(4 Suppl):243S-256S. PubMed ID: 1663860
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
    Mease PJ; Goffe BS; Metz J; VanderStoep A; Finck B; Burge DJ
    Lancet; 2000 Jul; 356(9227):385-90. PubMed ID: 10972371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis.
    Porter D; Madhok R; Hunter JA; Capell HA
    Ann Rheum Dis; 1992 Apr; 51(4):461-4. PubMed ID: 1350192
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A 12-month comparative trial of auranofin and D-penicillamine in rheumatoid arthritis.
    Felix-Davies DD; Stewart AM; Wilkinson BR; Bateman JR; Delamere JP
    Am J Med; 1983 Dec; 75(6A):138-41. PubMed ID: 6419596
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interventions for psoriatic arthritis.
    Jones G; Crotty M; Brooks P
    Cochrane Database Syst Rev; 2000; 2000(2):CD000212. PubMed ID: 10796328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Follow-up with OM-8980 after a double-blind study of OM-8980 and auranofin in rheumatoid arthritis.
    Vischer TL
    Clin Rheumatol; 1990 Sep; 9(3):356-61. PubMed ID: 2261735
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Auranofin: dose-related risk to benefit.
    Weiss TE
    Am J Med; 1983 Dec; 75(6A):128-32. PubMed ID: 6419594
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Auranofin in the treatment of steroid dependent asthma: a double blind study.
    Nierop G; Gijzel WP; Bel EH; Zwinderman AH; Dijkman JH
    Thorax; 1992 May; 47(5):349-54. PubMed ID: 1609377
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of psoriatic arthritis with sulphasalazine: a one year open study.
    Farr M; Kitas GD; Waterhouse L; Jubb R; Felix-Davies D; Bacon PA
    Clin Rheumatol; 1988 Sep; 7(3):372-7. PubMed ID: 2906579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Auranofin treatment in early rheumatoid arthritis may postpone early retirement. Results from a 2-year double blind trial.
    Borg G; Allander E; Berg E; Brodin U; From A; Trang L
    J Rheumatol; 1991 Jul; 18(7):1015-20. PubMed ID: 1920306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
    Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
    BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.